Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

Inclusion Criteria: * Patients with T2DM aged ≥18 years * 6.5%≤HbA1c≤11% * Clinically stable symptomatic heart failure (a) For HFrEF: (a) Ejection fraction (EF) less than or equal to (\<=) 40% and (b) diagnosis of chronic heart failure within the past 18 months (B) For HFpEF: (a) EF greater than (\>) 40%; (b) Diagnosis of chronic heart failure within the past 18 months * Symptoms of heart failure at visit 1 (NYHA II-IV) * KCCQ-OSS score \< 80 at screening visit * NT-proBNP \> 125 pg/mL, or NT proBNP \> 365 pg/mL in atrial fibrillation patients; Or BNP \> 35 pg/mL, or BNP \> 105 pg/mL in atrial fibrillation patients at screening visit * Subject must have received (and be receiving) at least one stable optimal dose of guidelines recommended HF drugs (e.g., ACEi, ARB, ARNI, beta blockers, oral diuretics, MRA) prior to visit 1 * eGFR≥30 ml/min/1.73m2 at screening visit (CKD-EPI formula) * Signed and dated written ICF Exclusion Criteria: * Pregnant and lactating women and women of childbearing age who do not want to use reliable contraception * Known allergy to Henagliflozin * Hospitalization for acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 4 weeks before the screening visit * Acute decompensated heart failure or hospitalization for decompensated heart failure within 4 weeks * History of heart transplantation or ventricular assist device (VAD), or intention to heart transplantation or VAD * Perinatal or chemotherapy-induced cardiomyopathy within 12 months * Documented untreated ventricular arrhythmias with syncope within 3 months * Diagnosed respiratory diseases * Type I diabetes * T2DM with history of ketoacidosis (DKA) * Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening visit * Symptomatic hypotension and/or systolic blood pressure \<90 mmHg at visit 0 or visit 1, or hypovolemia * History of recurrent urinary and reproductive tract infections * Current use or prior use of a SGLT-2i or GLP-1RA within 3 months * Diagnosed malignant tumors * Further exclusion criteria apply